TEVA

Teva Pharmaceutical Industries Limited

Fundamental data last updated:September 12, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Drug Manufacturers - Specialty & Generic

Exchange

NYSE

County of HQ

IL

Next Earnings Date

Pending Announcement

Business Summary

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

 


Analyze TEVA on TradingView

VALUATION

P/E

25.93

Market Cap ($M USD)

$41.13B

Forward P/E

8.21

PEG

0.04

PRICE TO SALES

2.34

PRICE TO BOOK

4.87

EV / EBITDA

16.27

5-Year Average P/E

Free Cash Flow Yield

4.65%

DCF Value

$21.33

Graham Number

$14.84

Price to FCF

21.53

EV to FCF

28.55

Earnings Yield

3.89%

FCF Yield

4.65%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$1.36

Next Year EPS Growth Estimate

$4.30

Next Year Revenue Growth Estimate

$19.30B

Return on Equity (ROE)

20.79%

FREE CASH FLOW

Operating Margin

19.38%

Debt-to-Equity

2.20

Piotroski F-Score

7

Altman Z-Score

0.93

Return on Invested Capital (ROIC)

12.62%

Current Ratio

1.01

Quick Ratio

0.78

Net Debt to EBITDA

4.00

Interest Coverage

3.97

Gross Profit margin

51.98%

FCF PER SHARE

$1.64

REVENUE PER SHARE

$15.08

Analyze TEVA on TradingView

Gainseekers Quantitative Analysis

Summary

The market seems to have mispriced Teva Pharmaceutical Industries Limited. Despite a snapshot price that traded above its DCF value, the forward P/E of 8.44 suggests significant growth expectations, especially with an earnings yield of 3.74%. However, the Altman Z-score of 0.94 raises red flags about financial distress, indicating potential risks. The Graham Number further underscores this mispricing, suggesting the stock is overvalued relative to its intrinsic worth. Overall, while growth is anticipated, the financial health remains questionable.

AI Exposure / Tech Reliance

Operating in the healthcare sector, Teva is well-positioned to leverage AI and tech advancements in drug manufacturing. The industry's shift towards personalized medicine and efficient drug production aligns with AI capabilities. This positioning could enhance Teva's operational efficiency and innovation pipeline.

The Bull Case

For value or GARP investors, Teva presents a compelling case. With a robust ROIC of 12.62% and a Piotroski F-Score of 7, the company demonstrates strong capital efficiency and financial health. The operating margin of 19.38% and a decent FCF yield suggest effective cost management and cash generation. These metrics indicate pricing power and a solid foundation for future growth.

The Bear Case

Teva's structural risks are glaring. The Price/Book ratio of 5.06 and Price/Sales of 2.43 highlight its overvaluation concerns. The quick ratio of 0.78 suggests liquidity issues, while the net debt to EBITDA ratio of 4.00 indicates significant leverage. Trading close to its 52-week high, the stock appears technically overextended, raising caution for potential investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$39.29

Institutional Ownership %

1-Year Beta

0.86

Insider Buying % (6 Mo)

Distance to 52-Week High

5.75%

Distance to 52-Week Low

57.56%

EARNINGS SURPRISE %

6.00%

50-DAY SMA

$32.47

200-DAY SMA

$27.67

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.